As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next?

41 psychedelic drug stocks trade on the various North American stock exchanges and in the past week 24 went up, 12 went down and 5 had no change in price.

It's now looking like the atai Life Sciences IPO and the MindMed uplisting to the Nasdaq could occur within weeks of each other. We point out what that means for investors in psychedelic stocks.

Drug development is expensive. It is also extremely lucrative. We take a close look at this revenue potential.

During this shortened week 15 psychedelic drug stocks went up in price,15 went down and 11 had no change for an overall sector change of +6.1%.